RY
RYTM.US Rhythm Pharmaceuticals Inc
- Market cap
- USD 8.02B
- P/E
- -
- P/B
- 84.72x
- ROE
- -96.8%
- Dividend yield
- 0.07%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RYTM.US undervalued?
Graham numberThe Graham number of Rhythm Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rhythm Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Rhythm Pharmaceuticals Inc yet.
Rhythm Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesi…
Full company profileRhythm Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rhythm Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 35.0K | 3.15M | 23.6M | 77.4M | 130M | 190M | 298M |
| Gross Profit | -144K | -223K | -442K | -834K | -690K | 2.56M | 21.5M | 68.1M | 117M | 170M | 260M |
| Operating Income | -25.9M | -32.4M | -78.4M | -146M | -137M | -170M | -179M | -184M | -266M | -192M | -187M |
| EBITDA | -25.8M | -32.2M | -78.0M | -145M | -136M | -169M | -174M | -168M | -238M | -174M | -174M |
| Net Income | -25.9M | -33.7M | -74.1M | -135M | -131M | -68.0M | -181M | -185M | -261M | -197M | -195M |
| EPS | -1.55 | -1.26 | -2.39 | -3.70 | -2.96 | -1.37 | -3.47 | -3.20 | -4.27 | -3.02 | -2.83 |
| Balance Sheet | |||||||||||
| Total Assets | 12.3M | 152M | 260M | 309M | 187M | 330M | 382M | 333M | 392M | 480M | 443M |
| Total Liabilities | 5.04M | 6.95M | 14.0M | 27.5M | 20.5M | 45.4M | 118M | 163M | 228M | 210M | 242M |
| Shareholders' Equity | 7.30M | 145M | 246M | 281M | 167M | 284M | 264M | 170M | 165M | 270M | 202M |
| Cash & Short-term Investments | 10.5M | 148M | 252M | 292M | 173M | 295M | 333M | 276M | 321M | 389M | 321M |
| Total Debt | - | - | - | 3.56M | 3.09M | 2.55M | 2.02M | 1.26M | 3.94M | 3.99M | 3.52M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -23.2M | -29.5M | -62.1M | -123M | -122M | -146M | -173M | -136M | -114M | -116M | -134M |
| Capital Expenditure | 1.06M | 133K | 722K | 3.39M | 214K | 5.43M | 4.28M | 47.0K | 0.00 | 953K | 667K |
| Free Cash Flow | -24.3M | -29.6M | -62.8M | -126M | -122M | -151M | -178M | -136M | -114M | -117M | -135M |
| Ratios | |||||||||||
| ROE | -354.6% | -23.3% | -30.1% | -47.9% | -78.5% | -23.9% | -68.5% | -108.8% | -158.4% | -72.8% | -96.8% |
| ROA | -209.7% | -22.2% | -28.5% | -43.6% | -69.9% | -20.6% | -47.4% | -55.5% | -66.4% | -40.9% | -44.0% |
| Net Profit Margin | - | - | - | - | -373,505.7% | -2,156.2% | -766.2% | -238.5% | -200.3% | -103.6% | -65.5% |
| Debt to Equity | - | - | - | 0.01x | 0.02x | 0.01x | 0.01x | 0.01x | 0.02x | 0.01x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rhythm Pharmaceuticals Inc dividends
- Dividend yield
- 0.07%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 5.38M | 0.08 | - |
| 2024 | USD 3.97M | 0.07 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Rhythm Pharmaceuticals Inc
- Insiders 0.70%
- Institutions 99.31%
- Public & others 0.00%
- Shares outstanding 69.3M
- Free float 56.5M
Top funds holding RYTM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.19M | 3.16% | +0.30% | Sep 2026 |
| PRIMECAP Odyssey Aggressive Growth | 1.94M | 2.79% | -2.64% | Sep 2026 |
| American Funds SMALLCAP World A | 1.77M | 2.55% | +3.64% | Sep 2026 |
| Polar Capital Biotech S Inc | 1.58M | 2.27% | 0.00% | Sep 2026 |
| Vanguard Small Cap Index | 1.55M | 2.23% | -1.80% | Sep 2026 |
| iShares Russell 2000 ETF | 1.47M | 2.12% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.27M | 1.83% | +2.68% | Oct 2026 |
| Federated Hermes Kaufmann R | 1.03M | 1.48% | 0.00% | Sep 2026 |
| PRIMECAP Odyssey Growth | 952K | 1.37% | -6.71% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 863K | 1.25% | -4.65% | Sep 2026 |
| JPMorgan Mid Cap Growth I | 839K | 1.21% | -1.57% | Sep 2026 |
| JPMorgan Growth Advantage A | 820K | 1.18% | -2.20% | Sep 2026 |
| T. Rowe Price New Horizons | 632K | 0.91% | -11.03% | Sep 2026 |
| Federated Hermes Kaufmann Small Cap A | 610K | 0.88% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 604K | 0.87% | +0.16% | Aug 2026 |
| Vanguard Explorer Inv | 583K | 0.84% | +5.50% | Sep 2026 |
| Pictet-Biotech P USD | 570K | 0.82% | +0.38% | Jul 2026 |
| Harbor Small Cap Growth Instl | 552K | 0.80% | +9.82% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 545K | 0.79% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 514K | 0.74% | -0.43% | Oct 2026 |
Top institutions holding RYTM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 6.67M | 9.62% | 0.00% | Jun 2026 |
| BlackRock Inc | 6.16M | 8.88% | -1.29% | Jun 2026 |
| Baker Bros Advisors LP | 5.60M | 8.09% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.14M | 4.53% | +3.16% | Jun 2026 |
| PRIMECAP Management Company | 3.06M | 4.42% | -3.30% | Sep 2026 |
| Vanguard Capital Management, LLC | 3.01M | 4.34% | +1.29% | Jun 2026 |
| JPMorgan Chase & Co | 2.65M | 3.83% | +70.74% | Jun 2026 |
| Perceptive Advisors LLC | 2.59M | 3.73% | +8.95% | Jun 2026 |
| State Street Corp | 2.57M | 3.71% | +13.28% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.57M | 3.70% | +55.07% | Jun 2026 |
| Westfield Capital Management Company, L.P. | 2.48M | 3.58% | +12.32% | Sep 2026 |
| The Goldman Sachs Group Inc | 2.13M | 3.07% | +8.20% | Jun 2026 |
| Federated Hermes Inc | 1.79M | 2.58% | +38.83% | Jun 2026 |
| Polar Capital Holdings PLC | 1.66M | 2.40% | +2.97% | Jun 2026 |
| Capital Research Global Investors | 1.59M | 2.30% | +4.08% | Sep 2026 |
| Geode Capital Management, LLC | 1.53M | 2.21% | +8.29% | Jun 2026 |
| Citadel Advisors Llc | 1.26M | 1.82% | -10.92% | Jun 2026 |
| Checkpoint Capital LP | 1.19M | 1.71% | -3.36% | Jun 2026 |
| Siren, L.L.C. | 1.14M | 1.64% | +56.62% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.11M | 1.60% | +57.99% | Jun 2026 |
Rhythm Pharmaceuticals Inc company profile
- Company name
- Rhythm Pharmaceuticals Inc
- Ticker
- RYTM.US
- Exchange
- USA Stocks
- Listed since
- Oct 5, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 414
- Fiscal year end
- December
- Address
- 222 Berkeley Street, Boston, MA, United States, 02116
- Phone
- 857 264 4280
- Website
- rhythmtx.com
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Rhythm Pharmaceuticals Inc management
10- Dr. David P. Meeker M.D.Chairman, President & CEO · born 1954
- Mr. Hunter C. Smith M.B.A.CFO & Treasurer · born 1969
- Dr. Alastair Garfield Ph.D.Chief Scientific Officer · born 1980
- Mr. Yann MazabraudExecutive VP & Head of International · born 1973
- Ms. Jennifer LeeExecutive VP & Head of North America · born 1975
- Mr. Christopher P. GermanCorporate Controller & Principal Accounting Officer · born 1972
- Mr. Joseph ShulmanChief Technical Officer · born 1975
- Mr. David ConnollyHead of Investor Relations & Corporate Communications
- Mr. Jim FlahertySenior VP & General Counsel
- Ms. Sarah RyanVice President of Sales & Marketing